Compounds > triazoles
Page last updated: 2024-08-24

triazoles and azd 6244

triazoles has been researched along with azd 6244 in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Acquaviva, J; Friedland, JC; He, S; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Wada, Y; Zhang, C1
Brodie, A; Golubeva, O; Kazi, A; Sabnis, GJ; Shah, P1
Acquaviva, J; Bates, RC; He, S; Jimenez, JP; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Zhang, C1
Abudayyeh, O; Barzily-Rokni, M; Cooper, ZA; Fisher, DE; Flaherty, KT; Frederick, DT; Garraway, LA; Hahn, WC; Haq, R; Johannessen, CM; Kim, JW; Konieczkowski, DJ; Mesirov, JP; Piris, A; Straussman, R; Tamayo, P; Wargo, JA1
Buijsman, RC; de Man, J; de Roos, JA; de Vetter, JR; Prinsen, MB; Spijkers-Hagelstein, JA; Uitdehaag, JC; van Doornmalen, AM; Zaman, GJ1
Byers, LA; Cardnell, RJ; Diao, L; Fowlkes, NW; Fradette, JJ; Gibbons, DL; Gibson, L; Konen, JM; Kovacs, JJ; Ochieng, JK; Padhye, A; Peng, DH; Rodriguez, BL; Wang, J1

Other Studies

6 other study(ies) available for triazoles and azd 6244

ArticleYear
Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:12

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Genes, ras; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Mutation; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays

2012
Effect of selumetinib on the growth of anastrozole-resistant tumors.
    Breast cancer research and treatment, 2013, Volume: 138, Issue:3

    Topics: Anastrozole; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; MAP Kinase Kinase 1; Mice; Mice, Nude; Nitriles; Ovariectomy; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays

2013
Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Molecular cancer therapeutics, 2014, Volume: 13, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; HSP90 Heat-Shock Proteins; Humans; Indoles; Melanoma; Mice, Nude; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mutation; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Sulfonamides; Triazoles; Vemurafenib; Xenograft Model Antitumor Assays

2014
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
    Cancer discovery, 2014, Volume: 4, Issue:7

    Topics: Anilides; Benzimidazoles; Benzocycloheptenes; Cell Line, Tumor; Cells, Cultured; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Indoles; MAP Kinase Signaling System; Melanocytes; Melanoma; Microphthalmia-Associated Transcription Factor; NF-kappa B p50 Subunit; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Pyridines; Quinolines; Sulfonamides; Triazoles

2014
Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aza Compounds; Benzimidazoles; beta Catenin; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Melanoma; Molecular Targeted Therapy; Mutation; Oxazoles; Oximes; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Quinolines; Sulfonamides; Triazoles; Vemurafenib

2015
Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
    Cancer research, 2021, 03-01, Volume: 81, Issue:5

    Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Benzimidazoles; Benzocycloheptenes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epithelial-Mesenchymal Transition; Humans; Lung Neoplasms; Mice, Inbred Strains; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Triazoles; Xenograft Model Antitumor Assays

2021